transit mrna Search Results


mirus mrna transfection kit  (Mirus Bio)
96
Mirus Bio mirus mrna transfection kit
A) Experimental workflow of GLORI-seq protocol to identify differential m 6 A following ZIKV infection (MOI 1, 48 hpi, n=3). B) Scatter plot showing ZIKV-induced changes in m 6 A levels of individual sites. Orange and blue dots represent upregulated (n=2004) and downregulated (n=502) m 6 A sites during ZIKV infection, respectively. C) Representative gene track plots of upregulated m 6 A in RIOK3 (upper panel), downregulated m 6 A in CIRBP (middle panel), and unchanged m 6 A in ACTB (lower panel). D) Metagene profiles showing the distributions of upregulated, downregulated, and unchanged m 6 A sites across the <t>mRNA</t> molecule. E) The top 6 motifs across upregulated, downregulated, and unchanged m 6 A sites and the proportion of m 6 A sites they contain. F) The absolute difference in m 6 A level of upregulated and downregulated m 6 A sites across the top 6 motifs. G) PANTHER GO enrichment analysis for genes with upregulated m 6 A sites using a binomial test with FDR correction (FDR p < 0.05).
Mirus Mrna Transfection Kit, supplied by Mirus Bio, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/transit+mrna/TransIT+-mRNA/bio_rxiv__64898__2026__03__27__714597-165-15-15
Average 96 stars, based on 1 article reviews
mirus mrna transfection kit - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
transit mrna  (Chromatographic Specialties Inc)
86
Chromatographic Specialties Inc transit mrna
A) Experimental workflow of GLORI-seq protocol to identify differential m 6 A following ZIKV infection (MOI 1, 48 hpi, n=3). B) Scatter plot showing ZIKV-induced changes in m 6 A levels of individual sites. Orange and blue dots represent upregulated (n=2004) and downregulated (n=502) m 6 A sites during ZIKV infection, respectively. C) Representative gene track plots of upregulated m 6 A in RIOK3 (upper panel), downregulated m 6 A in CIRBP (middle panel), and unchanged m 6 A in ACTB (lower panel). D) Metagene profiles showing the distributions of upregulated, downregulated, and unchanged m 6 A sites across the <t>mRNA</t> molecule. E) The top 6 motifs across upregulated, downregulated, and unchanged m 6 A sites and the proportion of m 6 A sites they contain. F) The absolute difference in m 6 A level of upregulated and downregulated m 6 A sites across the top 6 motifs. G) PANTHER GO enrichment analysis for genes with upregulated m 6 A sites using a binomial test with FDR correction (FDR p < 0.05).
Transit Mrna, supplied by Chromatographic Specialties Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/transit+mrna/mrna+transit/bio_rxiv__64898__2026__05__06__723222-74-14-15
Average 86 stars, based on 1 article reviews
transit mrna - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


A) Experimental workflow of GLORI-seq protocol to identify differential m 6 A following ZIKV infection (MOI 1, 48 hpi, n=3). B) Scatter plot showing ZIKV-induced changes in m 6 A levels of individual sites. Orange and blue dots represent upregulated (n=2004) and downregulated (n=502) m 6 A sites during ZIKV infection, respectively. C) Representative gene track plots of upregulated m 6 A in RIOK3 (upper panel), downregulated m 6 A in CIRBP (middle panel), and unchanged m 6 A in ACTB (lower panel). D) Metagene profiles showing the distributions of upregulated, downregulated, and unchanged m 6 A sites across the mRNA molecule. E) The top 6 motifs across upregulated, downregulated, and unchanged m 6 A sites and the proportion of m 6 A sites they contain. F) The absolute difference in m 6 A level of upregulated and downregulated m 6 A sites across the top 6 motifs. G) PANTHER GO enrichment analysis for genes with upregulated m 6 A sites using a binomial test with FDR correction (FDR p < 0.05).

Journal: bioRxiv

Article Title: Alternative polyadenylation drives isoform-dependent m⁶A remodeling during Zika virus infection

doi: 10.64898/2026.03.27.714597

Figure Lengend Snippet: A) Experimental workflow of GLORI-seq protocol to identify differential m 6 A following ZIKV infection (MOI 1, 48 hpi, n=3). B) Scatter plot showing ZIKV-induced changes in m 6 A levels of individual sites. Orange and blue dots represent upregulated (n=2004) and downregulated (n=502) m 6 A sites during ZIKV infection, respectively. C) Representative gene track plots of upregulated m 6 A in RIOK3 (upper panel), downregulated m 6 A in CIRBP (middle panel), and unchanged m 6 A in ACTB (lower panel). D) Metagene profiles showing the distributions of upregulated, downregulated, and unchanged m 6 A sites across the mRNA molecule. E) The top 6 motifs across upregulated, downregulated, and unchanged m 6 A sites and the proportion of m 6 A sites they contain. F) The absolute difference in m 6 A level of upregulated and downregulated m 6 A sites across the top 6 motifs. G) PANTHER GO enrichment analysis for genes with upregulated m 6 A sites using a binomial test with FDR correction (FDR p < 0.05).

Article Snippet: 2.5 μg of HCV PAMP RNA was transfected into cells for 8 h using the Mirus mRNA transfection kit.

Techniques: Infection

A) and B) The correlation of m 6 A levels for sites detected by GLORI-seq between three biologically independent samples of mock- (A) or ZIKV-infected (B) Huh7 cells (48 hpi, MOI 1). C) Boxplots showing distribution of methylation level of m 6 A sites in Mock and ZIKV conditions. D) Principal component analysis of GLORI-seq m 6 A stoichiometry rates for Mock and ZIKV conditions. E) Metagene profiles showing the distributions of Mock and ZIKV m 6 A sites across the mRNA molecule. F) The top 6 motifs across Mock and ZIKV m 6 A sites and the proportion of m 6 A sites they contain.

Journal: bioRxiv

Article Title: Alternative polyadenylation drives isoform-dependent m⁶A remodeling during Zika virus infection

doi: 10.64898/2026.03.27.714597

Figure Lengend Snippet: A) and B) The correlation of m 6 A levels for sites detected by GLORI-seq between three biologically independent samples of mock- (A) or ZIKV-infected (B) Huh7 cells (48 hpi, MOI 1). C) Boxplots showing distribution of methylation level of m 6 A sites in Mock and ZIKV conditions. D) Principal component analysis of GLORI-seq m 6 A stoichiometry rates for Mock and ZIKV conditions. E) Metagene profiles showing the distributions of Mock and ZIKV m 6 A sites across the mRNA molecule. F) The top 6 motifs across Mock and ZIKV m 6 A sites and the proportion of m 6 A sites they contain.

Article Snippet: 2.5 μg of HCV PAMP RNA was transfected into cells for 8 h using the Mirus mRNA transfection kit.

Techniques: Infection, Methylation

A) and B) RT-qPCR analysis (relative to RPL30 ) of RNA expression of ALCAM-S and ALCAM-L (A) and NHSL1-S and NHSL1-L (B) upon DENV infection (48 hpi, MOI 1). C) and D) RT-qPCR analysis (relative to RPL30 ) of RNA expression of ALCAM-S and ALCAM-L (C) and NHSL1-S and NHSL1-L (D) upon WNV infection (48 hpi, MOI 0.01). E) and F) RT-qPCR analysis (relative to RPL30) of RNA expression of ALCAM-S and ALCAM-L (E) and NHSL1-S and NHSL1-L (F) upon HCV infection (48 hpi, MOI 1). G) and H) RT-qPCR analysis (relative to RPL30 ) of RNA expression of ALCAM-S and ALCAM-L (G) and NHSL1-S and NHSL1-L (H) upon transfection with HCV PAMP (8 hrs).

Journal: bioRxiv

Article Title: Alternative polyadenylation drives isoform-dependent m⁶A remodeling during Zika virus infection

doi: 10.64898/2026.03.27.714597

Figure Lengend Snippet: A) and B) RT-qPCR analysis (relative to RPL30 ) of RNA expression of ALCAM-S and ALCAM-L (A) and NHSL1-S and NHSL1-L (B) upon DENV infection (48 hpi, MOI 1). C) and D) RT-qPCR analysis (relative to RPL30 ) of RNA expression of ALCAM-S and ALCAM-L (C) and NHSL1-S and NHSL1-L (D) upon WNV infection (48 hpi, MOI 0.01). E) and F) RT-qPCR analysis (relative to RPL30) of RNA expression of ALCAM-S and ALCAM-L (E) and NHSL1-S and NHSL1-L (F) upon HCV infection (48 hpi, MOI 1). G) and H) RT-qPCR analysis (relative to RPL30 ) of RNA expression of ALCAM-S and ALCAM-L (G) and NHSL1-S and NHSL1-L (H) upon transfection with HCV PAMP (8 hrs).

Article Snippet: 2.5 μg of HCV PAMP RNA was transfected into cells for 8 h using the Mirus mRNA transfection kit.

Techniques: Quantitative RT-PCR, RNA Expression, Infection, Transfection